Centers | ||
|
|
|
UCSC Chemical Screening Center | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | EU-OPENSCREEN |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Partnerships |
Events |
Jobs |
Argenta and ANTABIO Announce Drug Discovery CollaborationArgenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Vanderbilt Enters Into Collaboration With BMS to Develop Drugs to treat Parkinsons DiseaseVanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Bristol-Myers Squibb Company have entered into a broad collaboration agreement to co-develop new drugs to treat Parkinsons Disease. Under the collaboration agreement VCNDD will identify... View all |
No EVENTS for listing |
No Job Posts |
